Narrative review highlights deep B-cell depletion in autoimmune dermatological disorders, suggesting long-lasting remissions beyond conventional immunosuppressive drugs.
Chimeric antigen receptor (CAR) T-cells are autologous T-cells genetically engineered to express an antigen receptor that can recognise and kill cells expressing that target antigen. Originally developed for refractory or relapsed B-cell and plasma cell malignancies, CAR T-cell therapy is now being explored as a promising treatment for B-cell-mediated autoimmune diseases. CAR-T cells produce 'deep' B-cell depletion and cause 'resetting' of the immune system, thereby achieving long-lasting remissions and potentially even 'cure', addressing some major limitations of current immunosuppressive and biological therapies. This narrative review discusses the current status of CAR T-cell therapy, along with its potential future applications, for dermatological disorders.
No takes yet. Share an insight, caveat, or question.
Gowda et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: